Abstract Library

#4592 Uncovering cell-state heterogeneity in large-cell panNEC indicates potentially targetable aberrant brain type neuronal de-differentiation

Introduction: Classification and treatment of high-grade pancreatic neuroendocrine carcinoma (panNEC), particularly those with large-cell morphology, present significant clinical challenges due to considerable inter- and intra-patient tumour heterogeneity.

Conference:

Presenting Author: Debnath O

Authors: Debnath O, Berger H, Detjen K, Kirchner P, Marinoni I,

Keywords: pancreatic neuroendocrine carcinoma, single cell, personalised medicine,

#4258 Unanticipated heterogeneity in high-grade large-cell neuroendocrine carcinoma pinpoints cell sub-state specific therapeutic targets

Introduction: High-grade pancreatic neuroendocrine carcinoma (panNEC) pose challenges in terms of classification and treatment. While molecular genetics have made strides in deciphering significant inter-tumor heterogeneity, the extent of intra-tumoral heterogeneity and lineage plasticity remains unexplored.

Conference:

Presenting Author:

Authors: Debnath O, Detjen K, Berger H, Kirchner P, Marinoni I,

Keywords: PanNEC, Single cell RNAseq,

#3804 Wide molecular analysis of PanNET revealed that only MGMT promoter methylation seemed to correlate with Temozolomide response

Introduction: Temozolomide (TMZ) is an alkylating agent and is widely used in the treatment of PanNET. So far, only the MGMT status, defined by its immunohistochemical (IHC) expression or its promoter methylation, has been proposed as predictor of response to TMZ, but its value remains controversial.

Conference:

Presenting Author: Marinoni I

Authors: Cives M, Kirchner P, Palmirotta R, Lauricella E, de Mestier L,

Keywords: PanNET, Temozolomide, MGMT,

#3796 The effect of pseudohypoxia on the immune microenvironment of pancreatic neuroendocrine neoplasms (PanNEN)

Introduction: Pancreatic neuroendocrine tumors may develop sporadically or as part of an inherited disease, such as von Hippel-Lindau (VHL). VHL disease is caused by a germline pathogenic variant in the VHL gene encoding VHL protein (pVHL). Hypoxia inducible factor (HIF) is responsible for cellular oxygen supply. Its degradation is mediated in normoxic states via ubiquitination and inhibited by pVHL. Hence, pVHL deficiency leads to pseudohypoxia due to HIF overexpression. Several studies suggested immunomodulatory role for HIF in kidney cancer.

Conference:

Presenting Author:

Authors: Solomon Chmelnik A, Telerman A, Tirosh A,

Keywords: Pancreatic neuroendocrine tumor, VHL, DNA methylation, Immune cells, PD-L1,

#3174 Utility and timing of Technetium-99m-diethylene-triamine-penta-acetic acid measurement of glomerular filtration rate in patients undergoing peptide receptor radionuclide therapy

Introduction: Renal toxicity is a potential side effect of Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT). Some centres use serial Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR) measurements to detect early renal toxicity, but there is no consensus regarding the timing of serial scans nor its utility.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Agarwal V, Gordon S, Bailey D, Pavlakis N, Aslani A,

Keywords: Technetium-99m-diethylene-triaminepentaacetic acid (99mTc-DTPA) glomerular filtration rate (GFR), Lutetium-177 Peptide Receptor Radionuclide Therapy (177Lu-PRRT),